

# Oak Bluffs

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	2.47	3	NC*	Male	1.63	3	NC*
Female	1.03	4	NC*	Female	1.26	3	NC*
Total	3.51	7	200	Total	2.89	6	207
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.72	4	NC*	Male	0.48	0	NC*
Female	0.60	0	NC*	Female	0.46	0	NC*
Total	1.32	4	NC*	Total	0.94	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.12	0	NC*	Male	1.97	0	NC*
Female	15.57	23	148	Female	1.91	6	315 #+
Total	15.69	23	147	Total	3.88	6	155
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.82	0	NC*	Male	1.53	3	NC*
				Female	0.79	0	NC*
				Total	2.31	3	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	6.12	3	NC*	Female	1.80	2	NC*
Female	6.47	6	93				
Total	12.59	9	72				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.88	3	NC*	Male	1.03	2	NC*
Female	0.32	0	NC*	Female	1.20	2	NC*
Total	1.19	3	NC*	Total	2.23	4	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.35	0	NC*	Male	14.99	16	107
Female	0.27	2	NC*				
Total	0.62	2	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.45	3	NC*	Male	1.04	1	NC*
Female	0.97	0	NC*	Female	0.70	2	NC*
Total	2.41	3	NC*	Total	1.74	3	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.82	3	NC*	Male	0.52	1	NC*
Female	0.22	0	NC*				
Total	1.04	3	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.15	0	NC*	Male	0.32	0	NC*
Female	0.95	1	NC*	Female	0.81	1	NC*
Total	2.10	1	NC*	Total	1.13	1	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.56	1	NC*	Female	3.05	3	NC*
Female	0.26	1	NC*				
Total	0.82	2	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	7.71	7	91	Male	49.19	55	112
Female	6.77	3	NC*	Female	49.89	61	122
Total	14.48	10	69	Total	99.08	116	117

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Oakham

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.95	0	NC*	Male	0.70	0	NC*
Female	0.30	0	NC*	Female	0.49	0	NC*
Total	1.25	0	NC*	Total	1.19	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.32	0	NC*	Male	0.20	0	NC*
Female	0.24	0	NC*	Female	0.15	0	NC*
Total	0.57	0	NC*	Total	0.35	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.05	1	NC*	Male	0.82	2	NC*
Female	5.89	3	NC*	Female	0.63	0	NC*
Total	5.94	4	NC*	Total	1.46	2	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.35	0	NC*	Male	0.68	0	NC*
				Female	0.28	0	NC*
				Total	0.96	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	2.39	3	NC*	Female	0.69	0	NC*
Female	1.87	3	NC*				
Total	4.26	6	141				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.38	1	NC*	Male	0.42	0	NC*
Female	0.09	0	NC*	Female	0.35	0	NC*
Total	0.47	1	NC*	Total	0.76	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.16	0	NC*	Male	6.29	5	79
Female	0.12	1	NC*				
Total	0.27	1	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.63	0	NC*	Male	0.41	0	NC*
Female	0.33	1	NC*	Female	0.20	0	NC*
Total	0.96	1	NC*	Total	0.61	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.36	1	NC*	Male	0.22	0	NC*
Female	0.08	0	NC*				
Total	0.44	1	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.48	0	NC*	Male	0.14	0	NC*

Female	0.34	0	NC*	Female	0.37	0	NC*
Total	0.83	0	NC*	Total	0.51	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.24	0	NC*				
Female	0.08	0	NC*	Female	1.15	2	NC*
Total	0.32	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	3.17	4	NC*	Male	20.35	18	88
Female	2.23	2	NC*	Female	17.42	12	69
Total	5.40	6	111	Total	37.77	30	79

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Orange

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	4.50	5	111	Male	3.06	2	NC*
Female	1.97	0	NC*	Female	2.54	2	NC*
Total	6.47	5	77	Total	5.60	4	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.41	0	NC*	Male	0.89	0	NC*
Female	1.23	1	NC*	Female	0.88	0	NC*
Total	2.64	1	NC*	Total	1.77	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.22	0	NC*	Male	3.69	4	NC*
Female	30.33	20	66	Female	3.71	7	189
Total	30.55	20	65	Total	7.40	11	149
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.70	1	NC*	Male	2.87	3	NC*
				Female	1.52	2	NC*
				Total	4.39	5	114
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	11.22	7	62	Female	3.54	3	NC*
Female	12.39	13	105				
Total	23.60	20	85				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.64	1	NC*	Male	1.89	2	NC*
Female	0.60	0	NC*	Female	2.27	2	NC*
Total	2.24	1	NC*	Total	4.17	4	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.70	0	NC*	Male	28.37	17	60 #-
Female	0.59	1	NC*				

Total	1.30	1	NC*
<b><u>Kidney and Renal Pelvis</u></b>			
Male	2.72	2	NC*
Female	1.86	2	NC*
Total	4.58	4	NC*
<b><u>Larynx</u></b>			
Male	1.55	2	NC*
Female	0.42	0	NC*
Total	1.97	2	NC*
<b><u>Leukemia</u></b>			
Male	2.19	7	320 #+
Female	1.91	3	NC*
Total	4.10	10	244 #+
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	1.05	2	NC*
Female	0.50	0	NC*
Total	1.55	2	NC*
<b><u>Lung and Bronchus</u></b>			
Male	14.48	11	76
Female	12.80	10	78
Total	27.28	21	77

<b><u>Stomach</u></b>			
Male	1.89	4	NC*
Female	1.34	0	NC*
Total	3.23	4	NC*
<b><u>Testis</u></b>			
Male	1.05	0	NC*
<b><u>Thyroid</u></b>			
Male	0.61	2	NC*
Female	1.73	3	NC*
Total	2.34	5	214
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	5.85	7	120
<b><u>All Sites / Types</u></b>			
Male	92.18	78	85
Female	96.88	86	89
Total	189.06	164	87

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Orleans

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	9.99	20	200 ~+
Female	3.67	6	164
Total	13.66	26	190 ~+
<b><u>Brain and Other Central Nervous System</u></b>			
Male	1.91	1	NC*
Female	1.58	1	NC*
Total	3.49	2	NC*
<b><u>Breast</u></b>			
Male	0.42	1	NC*
Female	44.29	61	138 #+
Total	44.71	62	139 #+
<b><u>Cervix Uteri</u></b>			
Female	1.87	0	NC*

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	5.11	9	176
Female	3.40	8	235 #+
Total	8.51	17	200 #+
<b><u>Multiple Myeloma</u></b>			
Male	1.78	2	NC*
Female	1.51	0	NC*
Total	3.30	2	NC*
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	6.39	5	78
Female	6.01	9	150
Total	12.40	14	113
<b><u>Oral Cavity and Pharynx</u></b>			
Male	4.61	7	152
Female	2.41	3	NC*
Total	7.02	10	142

**Colon / Rectum**

Male	24.03	17	71
Female	23.12	18	78
Total	47.15	35	74

**Esophagus**

Male	3.00	2	NC*
Female	1.14	2	NC*
Total	4.14	4	NC*

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.71	0	NC*
Female	0.57	0	NC*
Total	1.27	0	NC*

**Kidney and Renal Pelvis**

Male	4.72	5	106
Female	2.97	0	NC*
Total	7.68	5	65

**Larynx**

Male	2.64	3	NC*
Female	0.64	0	NC*
Total	3.28	3	NC*

**Leukemia**

Male	3.84	3	NC*
Female	2.90	2	NC*
Total	6.74	5	74

**Liver and Intrahepatic Bile Ducts**

Male	1.83	3	NC*
Female	0.88	1	NC*
Total	2.71	4	NC*

**Lung and Bronchus**

Male	28.54	26	91
Female	21.14	17	80
Total	49.69	43	87

**Ovary**

Female	4.96	5	101
--------	------	---	-----

**Pancreas**

Male	3.85	6	156
Female	4.21	3	NC*
Total	8.06	9	112

**Prostate**

Male	53.94	93	172 ^+
------	-------	----	--------

**Stomach**

Male	4.01	2	NC*
Female	2.52	1	NC*
Total	6.53	3	NC*

**Testis**

Male	0.80	0	NC*
------	------	---	-----

**Thyroid**

Male	0.71	0	NC*
Female	1.68	1	NC*
Total	2.39	1	NC*

**Uteri, Corpus and Uterus, NOS**

Female	8.72	11	126
--------	------	----	-----

**All Sites / Types**

Male	174.83	219	125 ~+
Female	152.62	164	107
Total	327.46	383	117 ~+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Otis****Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.68	1	NC*	Male	0.50	0	NC*
Female	0.24	0	NC*	Female	0.36	0	NC*
Total	0.93	1	NC*	Total	0.86	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			

Male	0.23	2	NC*
Female	0.17	1	NC*
Total	0.41	3	NC*
<b>Breast</b>			
Male	0.03	0	NC*
Female	4.18	3	NC*
Total	4.21	3	NC*
<b>Cervix Uteri</b>			
Female	0.26	1	NC*
<b>Colon / Rectum</b>			
Male	1.73	2	NC*
Female	1.53	2	NC*
Total	3.26	4	NC*
<b>Esophagus</b>			
Male	0.26	0	NC*
Female	0.07	0	NC*
Total	0.34	0	NC*
<b>Hodgkin's Disease (Hodgkin Lymphoma)</b>			
Male	0.12	0	NC*
Female	0.09	0	NC*
Total	0.21	0	NC*
<b>Kidney and Renal Pelvis</b>			
Male	0.44	0	NC*
Female	0.24	0	NC*
Total	0.68	0	NC*
<b>Larynx</b>			
Male	0.25	1	NC*
Female	0.06	0	NC*
Total	0.31	1	NC*
<b>Leukemia</b>			
Male	0.35	0	NC*
Female	0.25	1	NC*
Total	0.60	1	NC*
<b>Liver and Intrahepatic Bile Ducts</b>			
Male	0.17	0	NC*
Female	0.06	0	NC*
Total	0.23	0	NC*
<b>Lung and Bronchus</b>			
Male	2.29	1	NC*
Female	1.65	3	NC*
Total	3.94	4	NC*

Male	0.14	0	NC*
Female	0.11	0	NC*
Total	0.25	0	NC*
<b>Non-Hodgkin('s) Lymphoma</b>			
Male	0.60	0	NC*
Female	0.49	1	NC*
Total	1.08	1	NC*
<b>Oral Cavity and Pharynx</b>			
Male	0.47	0	NC*
Female	0.20	0	NC*
Total	0.67	0	NC*
<b>Ovary</b>			
Female	0.49	1	NC*
<b>Pancreas</b>			
Male	0.30	0	NC*
Female	0.28	0	NC*
Total	0.58	0	NC*
<b>Prostate</b>			
Male	4.55	5	110
<b>Stomach</b>			
Male	0.29	0	NC*
Female	0.17	0	NC*
Total	0.46	0	NC*
<b>Testis</b>			
Male	0.19	0	NC*
<b>Thyroid</b>			
Male	0.11	0	NC*
Female	0.27	0	NC*
Total	0.38	0	NC*
<b>Uteri, Corpus and Uterus, NOS</b>			
Female	0.79	1	NC*
<b>All Sites / Types</b>			
Male	14.68	12	82
Female	12.89	15	116
Total	27.57	27	98

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the **p** ≤ 0.05 level

~ indicates statistical significance at the **p** ≤ 0.01 level, as well as at the **p** ≤ 0.05 level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Oxford

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	7.36	8	109	Male	5.21	6	115
Female	2.87	1	NC*	Female	4.15	3	NC*
Total	10.23	9	88	Total	9.36	9	96
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.42	5	207	Male	1.46	2	NC*
Female	1.99	4	NC*	Female	1.32	2	NC*
Total	4.40	9	205	Total	2.78	4	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.35	1	NC*	Male	6.27	8	128
Female	48.74	48	98	Female	5.67	5	88
Total	49.09	49	100	Total	11.95	13	109
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	2.90	5	172	Male	4.89	5	102
				Female	2.38	2	NC*
				Total	7.27	7	96
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	18.39	13	71	Female	5.73	7	122
Female	17.96	19	106				
Total	36.35	32	88				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	2.74	2	NC*	Male	3.15	5	159
Female	0.87	1	NC*	Female	3.32	5	151
Total	3.61	3	NC*	Total	6.47	10	155
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.27	1	NC*	Male	46.57	40	86
Female	1.01	0	NC*				
Total	2.28	1	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	4.54	11	242 #+	Male	3.15	1	NC*
Female	2.89	4	NC*	Female	1.95	2	NC*
Total	7.44	15	202 #+	Total	5.10	3	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.59	1	NC*	Male	1.98	4	NC*
Female	0.67	1	NC*				
Total	3.26	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	3.66	7	191	Male	1.10	2	NC*
Female	2.94	2	NC*	Female	3.01	1	NC*
Total	6.60	9	136	Total	4.10	3	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.76	0	NC*	Female	9.37	6	64
Female	0.74	0	NC*				
Total	2.50	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	23.65	20	85	Male	152.87	153	100
Female	19.66	15	76	Female	150.84	145	96

Total	43.31	35	81	Total	303.71	298	98
-------	-------	----	----	-------	--------	-----	----

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Palmer

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	8.45	12	142	Male	5.48	4	NC*
Female	3.52	3	NC*	Female	4.35	4	NC*
Total	11.97	15	125	Total	9.84	8	81
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.44	2	NC*	Male	1.64	0	NC*
Female	2.08	3	NC*	Female	1.54	1	NC*
Total	4.52	5	111	Total	3.18	1	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.39	0	NC*	Male	6.66	4	NC*
Female	52.23	44	84	Female	6.49	3	NC*
Total	52.62	44	84	Total	13.16	7	53
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	2.87	7	244	Male	5.05	5	99
				Female	2.65	2	NC*
				Total	7.70	7	91
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	20.90	21	100	Female	6.07	13	214 #+
Female	22.15	17	77				
Total	43.06	38	88				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	2.94	1	NC*	Male	3.48	4	NC*
Female	1.08	1	NC*	Female	4.06	4	NC*
Total	4.02	2	NC*	Total	7.54	8	106
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.21	0	NC*	Male	51.15	49	96
Female	0.99	1	NC*				
Total	2.20	1	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	4.87	6	123	Male	3.51	5	142
Female	3.24	2	NC*	Female	2.41	4	NC*
Total	8.11	8	99	Total	5.92	9	152
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.75	8	291 #+	Male	1.84	2	NC*
Female	0.73	2	NC*				
Total	3.47	10	288 ~+				

<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	3.94	3	NC*	Male	1.06	0	NC*
Female	3.28	6	183	Female	2.89	5	173
Total	7.22	9	125	Total	3.95	5	127
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.88	5	266	Female	10.07	9	89
Female	0.88	2	NC*				
Total	2.76	7	254 #+				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	26.43	35	132	Male	167.46	178	106
Female	22.41	20	89	Female	168.68	158	94
Total	48.84	55	113	Total	336.14	336	100

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Paxton

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	3.38	3	NC*	Male	2.23	4	NC*
Female	1.17	0	NC*	Female	1.63	2	NC*
Total	4.55	3	NC*	Total	3.87	6	155
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.99	0	NC*	Male	0.67	0	NC*
Female	0.78	2	NC*	Female	0.55	1	NC*
Total	1.77	2	NC*	Total	1.23	1	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.16	1	NC*	Male	2.67	2	NC*
Female	20.29	20	99	Female	2.30	1	NC*
Total	20.46	21	103	Total	4.97	3	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.10	1	NC*	Male	2.17	0	NC*
				Female	0.99	0	NC*
				Total	3.16	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	8.44	2	NC*	Female	2.35	1	NC*
Female	7.30	6	82				
Total	15.74	8	51				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.26	0	NC*	Male	1.44	2	NC*
Female	0.36	0	NC*	Female	1.37	1	NC*
Total	1.61	0	NC*	Total	2.81	3	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			

Male	0.44	0	NC*
Female	0.35	0	NC*
Total	0.79	0	NC*

#### **Kidney and Renal Pelvis**

Male	2.04	3	NC*
Female	1.21	1	NC*
Total	3.25	4	NC*

#### **Larynx**

Male	1.19	1	NC*
Female	0.29	0	NC*
Total	1.48	1	NC*

#### **Leukemia**

Male	1.56	2	NC*
Female	1.17	0	NC*
Total	2.73	2	NC*

#### **Liver and Intrahepatic Bile Ducts**

Male	0.79	0	NC*
Female	0.30	0	NC*
Total	1.10	0	NC*

#### **Lung and Bronchus**

Male	11.05	5	45
Female	8.39	6	72
Total	19.44	11	57

Male	22.03	21	95
------	-------	----	----

#### **Stomach**

Male	1.42	1	NC*
Female	0.78	1	NC*
Total	2.20	2	NC*

#### **Testis**

Male	0.61	1	NC*
------	------	---	-----

#### **Thyroid**

Male	0.42	1	NC*
Female	1.10	2	NC*
Total	1.52	3	NC*

#### **Uteri, Corpus and Uterus, NOS**

Female	4.01	4	NC*
--------	------	---	-----

#### **All Sites / Types**

Male	69.44	53	76 #-
Female	62.08	53	85
Total	131.52	106	81 #-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## **Peabody**

**Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>			
Male	34.79	40	115
Female	13.89	15	108
Total	48.68	55	113

#### **Brain and Other Central Nervous System**

Male	10.32	8	78
Female	8.57	5	58
Total	18.88	13	69

#### **Breast**

Male	1.66	2	NC*
Female	220.83	246	111
Total	222.48	248	111

#### **Cervix Uteri**

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Melanoma of Skin</u></b>			
Male	23.15	28	121
Female	18.07	14	77
Total	41.22	42	102

#### **Multiple Myeloma**

Male	6.84	10	146
Female	6.29	10	159
Total	13.13	20	152

#### **Non-Hodgkin('s) Lymphoma**

Male	27.82	34	122
Female	26.34	33	125
Total	54.17	67	124

#### **Oral Cavity and Pharynx**

Male	21.89	23	105
------	-------	----	-----

Female	12.08	10	83	Female	10.98	11	100
				Total	32.87	34	103
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	86.90	100	115				
Female	86.93	93	107	Female	25.60	24	94
Total	173.84	193	111				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	12.70	16	126	Male	14.70	16	109
Female	4.25	1	NC*	Female	16.15	14	87
Total	16.94	17	100	Total	30.85	30	97
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	5.02	8	159	Male	223.34	253	113
Female	3.99	4	NC*				
Total	9.01	12	133				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	20.69	32	155 #+	Male	14.57	9	62
Female	13.47	17	126	Female	9.35	9	96
Total	34.16	49	143 #+	Total	23.92	18	75
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	11.99	17	142	Male	7.49	6	80
Female	3.14	3	NC*				
Total	15.13	20	132				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	16.16	13	80	Male	4.55	2	NC*
Female	13.11	16	122	Female	12.11	13	107
Total	29.27	29	99	Total	16.66	15	90
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	8.07	13	161				
Female	3.52	4	NC*	Female	43.12	49	114
Total	11.59	17	147				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	112.73	142	126 ~+	Male	712.19	824	116 ^+
Female	93.81	110	117	Female	695.68	759	109 #+
Total	206.54	252	122 ~+	Total	1407.86	1583	112 ^+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Pelham

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.07	0	NC*	Male	0.70	1	NC*
Female	0.30	0	NC*	Female	0.49	0	NC*

Total	1.37	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>			
Male	0.31	0	NC*
Female	0.23	0	NC*
Total	0.54	0	NC*
<b><u>Breast</u></b>			
Male	0.05	0	NC*
Female	5.83	7	120
Total	5.88	7	119
<b><u>Cervix Uteri</u></b>			
Female	0.35	0	NC*
<b><u>Colon / Rectum</u></b>			
Male	2.66	2	NC*
Female	1.90	2	NC*
Total	4.56	4	NC*
<b><u>Esophagus</u></b>			
Male	0.39	0	NC*
Female	0.09	0	NC*
Total	0.49	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	0.15	0	NC*
Female	0.11	0	NC*
Total	0.26	0	NC*
<b><u>Kidney and Renal Pelvis</u></b>			
Male	0.63	3	NC*
Female	0.33	1	NC*
Total	0.96	4	NC*
<b><u>Larynx</u></b>			
Male	0.37	0	NC*
Female	0.08	0	NC*
Total	0.45	0	NC*
<b><u>Leukemia</u></b>			
Male	0.49	0	NC*
Female	0.32	0	NC*
Total	0.80	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	0.25	0	NC*
Female	0.08	0	NC*
Total	0.33	0	NC*
<b><u>Lung and Bronchus</u></b>			
Male	3.43	2	NC*
Female	2.31	0	NC*
Total	5.74	2	NC*

Total	1.19	1	NC*
<b><u>Multiple Myeloma</u></b>			
Male	0.21	0	NC*
Female	0.15	0	NC*
Total	0.36	0	NC*
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.85	0	NC*
Female	0.64	0	NC*
Total	1.48	0	NC*
<b><u>Oral Cavity and Pharynx</u></b>			
Male	0.68	0	NC*
Female	0.27	0	NC*
Total	0.95	0	NC*
<b><u>Ovary</u></b>			
Female	0.68	0	NC*
<b><u>Pancreas</u></b>			
Male	0.46	0	NC*
Female	0.36	0	NC*
Total	0.81	0	NC*
<b><u>Prostate</u></b>			
Male	6.88	5	73
<b><u>Stomach</u></b>			
Male	0.45	0	NC*
Female	0.20	0	NC*
Total	0.65	0	NC*
<b><u>Testis</u></b>			
Male	0.21	0	NC*
<b><u>Thyroid</u></b>			
Male	0.14	1	NC*
Female	0.36	0	NC*
Total	0.50	1	NC*
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	1.14	3	NC*
<b><u>All Sites / Types</u></b>			
Male	21.79	18	83
Female	17.37	14	81
Total	39.16	32	82

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Pembroke

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	7.71	23	298 ^+	Male	5.99	5	84
Female	2.78	3	NC*	Female	4.54	6	132
Total	10.49	26	248 ^+	Total	10.53	11	104
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.84	1	NC*	Male	1.62	3	NC*
Female	2.16	6	278 #+	Female	1.34	3	NC*
Total	5.01	7	140	Total	2.96	6	203
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.39	0	NC*	Male	7.07	11	156
Female	53.59	63	118	Female	5.79	4	NC*
Total	53.99	63	117	Total	12.86	15	117
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	3.26	7	215	Male	5.83	4	NC*
<b><u>Colon / Rectum</u></b>				Female	2.53	2	NC*
Male	19.53	14	72	Total	8.36	6	72
Female	17.34	14	81	<b><u>Ovary</u></b>			
Total	36.86	28	76	Female	6.30	9	143
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	3.14	5	159	Male	3.45	6	174
Female	0.84	3	NC*	Female	3.21	4	NC*
Total	3.98	8	201	Total	6.66	10	150
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.48	1	NC*	Male	52.06	57	109
Female	1.10	0	NC*	<b><u>Stomach</u></b>			
Total	2.58	1	NC*	Male	3.40	5	147
<b><u>Kidney and Renal Pelvis</u></b>				Female	1.88	1	NC*
Male	5.25	8	152	Total	5.27	6	114
Female	3.03	1	NC*	<b><u>Testis</u></b>			
Total	8.28	9	109	Male	2.26	1	NC*
<b><u>Larynx</u></b>				<b><u>Thyroid</u></b>			
Male	3.04	1	NC*	Male	1.32	1	NC*
Female	0.73	0	NC*	Female	3.40	5	147
Total	3.77	1	NC*	Total	4.72	6	127
<b><u>Leukemia</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	4.08	3	NC*	Female	10.33	16	155
Female	3.10	2	NC*	<b><u>All Sites / Types</u></b>			
Total	7.18	5	70				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>							
Male	2.03	0	NC*				
Female	0.73	1	NC*				
Total	2.76	1	NC*				
<b><u>Lung and Bronchus</u></b>							

Male	25.95	28	108
Female	20.20	28	139
Total	46.15	56	121

Male	169.67	189	111
Female	158.98	189	119 #+
Total	328.65	378	115 ~+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Pepperell

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	4.56	10	219 #+
Female	1.82	2	NC*
Total	6.38	12	188

<b><u>Brain and Other Central Nervous System</u></b>			
Male	1.91	2	NC*
Female	1.47	1	NC*
Total	3.38	3	NC*

<b><u>Breast</u></b>			
Male	0.24	0	NC*
Female	35.46	34	96
Total	35.70	34	95

<b><u>Cervix Uteri</u></b>			
Female	2.26	4	NC*

<b><u>Colon / Rectum</u></b>			
Male	11.63	8	69
Female	11.36	14	123
Total	23.00	22	96

<b><u>Esophagus</u></b>			
Male	1.93	1	NC*
Female	0.55	1	NC*
Total	2.48	2	NC*

<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	1.06	0	NC*
Female	0.80	3	NC*
Total	1.85	3	NC*

<b><u>Kidney and Renal Pelvis</u></b>			
Male	3.31	4	NC*
Female	1.99	4	NC*
Total	5.30	8	151

<b><u>Larynx</u></b>			
Male	1.90	2	NC*

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	3.84	6	156
Female	3.09	0	NC*
Total	6.93	6	87

<b><u>Multiple Myeloma</u></b>			
Male	0.98	1	NC*
Female	0.87	1	NC*
Total	1.86	2	NC*

<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	4.53	2	NC*
Female	3.84	8	208
Total	8.36	10	120

<b><u>Oral Cavity and Pharynx</u></b>			
Male	3.71	1	NC*
Female	1.67	2	NC*
Total	5.38	3	NC*

<b><u>Ovary</u></b>			
Female	4.20	1	NC*

<b><u>Pancreas</u></b>			
Male	2.09	3	NC*
Female	2.09	1	NC*
Total	4.18	4	NC*

<b><u>Prostate</u></b>			
Male	31.39	26	83

<b><u>Stomach</u></b>			
Male	2.04	1	NC*
Female	1.25	0	NC*
Total	3.29	1	NC*

<b><u>Testis</u></b>			
Male	1.68	2	NC*

Female	0.47	0	NC*
Total	2.37	2	NC*

#### Leukemia

Male	2.63	4	NC*
Female	2.11	4	NC*
Total	4.73	8	169

#### Liver and Intrahepatic Bile Ducts

Male	1.27	1	NC*
Female	0.48	1	NC*
Total	1.75	2	NC*

#### Lung and Bronchus

Male	15.66	8	51
Female	13.00	11	85
Total	28.65	19	66

#### Thyroid

Male	0.90	0	NC*
Female	2.40	3	NC*
Total	3.30	3	NC*

#### Uteri, Corpus and Uterus, NOS

Female	6.74	3	NC*
--------	------	---	-----

#### All Sites / Types

Male	104.27	89	85
Female	105.11	102	97
Total	209.38	191	91

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Peru

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	0.53	0	NC*
Female	0.14	0	NC*
Total	0.67	0	NC*

#### **Brain and Other Central Nervous System**

Male	0.16	0	NC*
Female	0.12	0	NC*
Total	0.28	0	NC*

#### **Breast**

Male	0.03	0	NC*
Female	2.70	0	NC*
Total	2.72	0	NC*

#### **Cervix Uteri**

Female	0.17	0	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	1.31	0	NC*
Female	0.88	0	NC*
Total	2.20	0	NC*

#### **Esophagus**

Male	0.19	0	NC*
Female	0.04	0	NC*

#### **Melanoma of Skin**

Male	0.36	0	NC*
Female	0.24	1	NC*
Total	0.60	1	NC*

#### **Multiple Myeloma**

Male	0.10	0	NC*
Female	0.07	0	NC*
Total	0.17	0	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	0.44	0	NC*
Female	0.30	0	NC*
Total	0.74	0	NC*

#### **Oral Cavity and Pharynx**

Male	0.34	0	NC*
Female	0.13	0	NC*
Total	0.47	0	NC*

#### **Ovary**

Female	0.32	0	NC*
--------	------	---	-----

#### **Pancreas**

Male	0.23	0	NC*
Female	0.16	0	NC*

Total	0.24	0	NC*
<b>Hodgkin's Disease (Hodgkin Lymphoma)</b>			
Male	0.08	0	NC*
Female	0.06	0	NC*
Total	0.14	0	NC*
<b>Kidney and Renal Pelvis</b>			
Male	0.32	0	NC*
Female	0.16	0	NC*
Total	0.47	0	NC*
<b>Larynx</b>			
Male	0.18	0	NC*
Female	0.04	0	NC*
Total	0.22	0	NC*
<b>Leukemia</b>			
Male	0.26	0	NC*
Female	0.16	0	NC*
Total	0.42	0	NC*
<b>Liver and Intrahepatic Bile Ducts</b>			
Male	0.12	0	NC*
Female	0.04	0	NC*
Total	0.16	0	NC*
<b>Lung and Bronchus</b>			
Male	1.65	2	NC*
Female	1.04	0	NC*
Total	2.68	2	NC*

Total	0.39	0	NC*
<b>Prostate</b>			
Male	3.22	1	NC*
<b>Stomach</b>			
Male	0.23	0	NC*
Female	0.09	0	NC*
Total	0.32	0	NC*
<b>Testis</b>			
Male	0.12	0	NC*
<b>Thyroid</b>			
Male	0.07	0	NC*
Female	0.18	1	NC*
Total	0.26	1	NC*
<b>Uteri, Corpus and Uterus, NOS</b>			
Female	0.52	0	NC*
<b>All Sites / Types</b>			
Male	10.68	3	NC*
Female	8.11	3	NC*
Total	18.79	6	32 ~-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Petersham

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b>Bladder, Urinary</b>			
Male	0.91	1	NC*
Female	0.38	1	NC*
Total	1.28	2	NC*
<b>Brain and Other Central Nervous System</b>			
Male	0.26	0	NC*
Female	0.20	0	NC*
Total	0.46	0	NC*
<b>Breast</b>			
Male	0.04	1	NC*
Female	5.50	5	91
Total	5.54	6	108

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b>Melanoma of Skin</b>			
Male	0.59	0	NC*
Female	0.44	0	NC*
Total	1.03	0	NC*
<b>Multiple Myeloma</b>			
Male	0.18	0	NC*
Female	0.17	0	NC*
Total	0.34	0	NC*
<b>Non-Hodgkin('s) Lymphoma</b>			
Male	0.71	2	NC*
Female	0.67	0	NC*
Total	1.38	2	NC*

<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.28	1	NC*	Male	0.56	0	NC*
				Female	0.28	0	NC*
				Total	0.84	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	2.24	4	NC*	Female	0.63	2	NC*
Female	2.38	0	NC*				
Total	4.62	4	NC*				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.32	0	NC*	Male	0.38	0	NC*
Female	0.12	0	NC*	Female	0.43	2	NC*
Total	0.44	0	NC*	Total	0.81	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.12	0	NC*	Male	5.55	7	126
Female	0.09	0	NC*				
Total	0.21	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.53	2	NC*	Male	0.38	0	NC*
Female	0.34	0	NC*	Female	0.26	0	NC*
Total	0.87	2	NC*	Total	0.64	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.30	0	NC*	Male	0.17	0	NC*
Female	0.08	0	NC*				
Total	0.38	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.41	0	NC*	Male	0.11	0	NC*
Female	0.33	0	NC*	Female	0.27	0	NC*
Total	0.75	0	NC*	Total	0.38	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.20	0	NC*	Female	1.07	1	NC*
Female	0.09	0	NC*				
Total	0.30	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	2.84	2	NC*	Male	18.01	19	105
Female	2.36	1	NC*	Female	17.72	16	90
Total	5.20	3	NC*	Total	35.73	35	98

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Phillipston

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

<u>Bladder, Urinary</u>	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>	<u>Melanoma of Skin</u>	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
-------------------------	------------	------------	------------	-------------------------	------------	------------	------------

Male	0.93	0	NC*
Female	0.24	0	NC*
Total	1.17	0	NC*

#### **Brain and Other Central Nervous System**

Male	0.36	1	NC*
Female	0.23	0	NC*
Total	0.59	1	NC*

#### **Breast**

Male	0.05	0	NC*
Female	5.31	1	NC*
Total	5.36	1	NC*

#### **Cervix Uteri**

Female	0.37	0	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	2.36	1	NC*
Female	1.53	0	NC*
Total	3.89	1	NC*

#### **Esophagus**

Male	0.38	0	NC*
Female	0.07	0	NC*
Total	0.45	0	NC*

#### **Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.20	0	NC*
Female	0.14	1	NC*
Total	0.33	1	NC*

#### **Kidney and Renal Pelvis**

Male	0.64	0	NC*
Female	0.29	0	NC*
Total	0.93	0	NC*

#### **Larynx**

Male	0.37	1	NC*
Female	0.07	0	NC*
Total	0.44	1	NC*

#### **Leukemia**

Male	0.50	0	NC*
Female	0.31	0	NC*
Total	0.81	0	NC*

#### **Liver and Intrahepatic Bile Ducts**

Male	0.25	0	NC*
Female	0.07	0	NC*
Total	0.31	0	NC*

#### **Lung and Bronchus**

Male	3.16	1	NC*
Female	1.90	2	NC*
Total	5.06	3	NC*

Male	0.74	0	NC*
Female	0.48	0	NC*
Total	1.22	0	NC*

#### **Multiple Myeloma**

Male	0.19	0	NC*
Female	0.12	1	NC*
Total	0.32	1	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	0.88	1	NC*
Female	0.56	0	NC*
Total	1.44	1	NC*

#### **Oral Cavity and Pharynx**

Male	0.71	0	NC*
Female	0.24	0	NC*
Total	0.95	0	NC*

#### **Ovary**

Female	0.64	0	NC*
--------	------	---	-----

#### **Pancreas**

Male	0.42	0	NC*
Female	0.28	0	NC*
Total	0.70	0	NC*

#### **Prostate**

Male	6.37	4	NC*
------	------	---	-----

#### **Stomach**

Male	0.41	0	NC*
Female	0.17	0	NC*
Total	0.58	0	NC*

#### **Testis**

Male	0.31	1	NC*
------	------	---	-----

#### **Thyroid**

Male	0.17	0	NC*
Female	0.41	0	NC*
Total	0.58	0	NC*

#### **Uteri, Corpus and Uterus, NOS**

Female	1.00	0	NC*
--------	------	---	-----

#### **All Sites / Types**

Male	20.77	11	53 #–
Female	15.46	6	39 #–
Total	36.23	17	47 ^–

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Pittsfield

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	36.46	28	77	Male	22.34	16	72
Female	15.43	14	91	Female	17.80	12	67
Total	51.88	42	81	Total	40.14	28	70
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	9.65	9	93	Male	6.88	10	145
Female	8.51	6	71	Female	6.68	4	NC*
Total	18.15	15	83	Total	13.56	14	103
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	1.65	1	NC*	Male	27.40	18	66
Female	217.96	226	104	Female	27.74	17	61 #~
Total	219.61	227	103	Total	55.14	35	63 ~-
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	11.32	13	115	Male	20.47	15	73
				Female	11.24	3	NC*
				Total	31.71	18	57 #~
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	89.61	85	95	Female	25.16	28	111
Female	97.11	75	77 #~				
Total	186.72	160	86				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	12.24	9	74	Male	14.81	21	142
Female	4.74	3	NC*	Female	17.81	10	56
Total	16.98	12	71	Total	32.62	31	95
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	4.64	4	NC*	Male	215.29	168	78 ^~
Female	3.83	1	NC*				
Total	8.47	5	59				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	19.90	13	65	Male	15.06	10	66
Female	13.83	9	65	Female	10.52	8	76
Total	33.72	22	65 #~	Total	25.58	18	70
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	11.24	10	89	Male	6.82	4	NC*
Female	3.09	4	NC*				
Total	14.34	14	98				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	16.23	15	92	Male	4.09	3	NC*
Female	13.77	6	44 #~	Female	11.18	11	98
Total	29.99	21	70	Total	15.28	14	92
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	7.72	3	NC*	Female	42.36	34	80
Female	3.82	3	NC*				

Total	11.54	6	52
<b><u>Lung and Bronchus</u></b>			
Male	111.39	94	84
Female	96.82	83	86
Total	208.21	177	85 #-

#### **All Sites / Types**

Male	701.74	584	83 ^-
Female	715.26	606	85 ^-
Total	1417.00	1190	84 ^-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## **Plainfield**

**Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>			
Male	0.46	0	NC*
Female	0.13	0	NC*
Total	0.59	0	NC*

#### **Brain and Other Central Nervous System**

Male	0.12	0	NC*
Female	0.09	0	NC*
Total	0.21	0	NC*

#### **Breast**

Male	0.02	0	NC*
Female	2.25	4	NC*
Total	2.28	4	NC*

#### **Cervix Uteri**

Female	0.12	0	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	1.14	0	NC*
Female	0.79	0	NC*
Total	1.93	0	NC*

#### **Esophagus**

Male	0.16	0	NC*
Female	0.04	0	NC*
Total	0.20	0	NC*

#### **Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.05	0	NC*
Female	0.04	0	NC*
Total	0.09	0	NC*

#### **Kidney and Renal Pelvis**

Male	0.26	0	NC*
Female	0.13	0	NC*
Total	0.40	0	NC*

#### **Melanoma of Skin**

Male	0.29	0	NC*
Female	0.18	0	NC*
Total	0.46	0	NC*

#### **Multiple Myeloma**

Male	0.09	0	NC*
Female	0.06	0	NC*
Total	0.15	0	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	0.34	0	NC*
Female	0.25	0	NC*
Total	0.60	0	NC*

#### **Oral Cavity and Pharynx**

Male	0.27	0	NC*
Female	0.11	0	NC*
Total	0.38	0	NC*

#### **Ovary**

Female	0.26	0	NC*
--------	------	---	-----

#### **Pancreas**

Male	0.19	0	NC*
Female	0.15	0	NC*
Total	0.34	0	NC*

#### **Prostate**

Male	2.77	2	NC*
------	------	---	-----

#### **Stomach**

Male	0.19	0	NC*
Female	0.08	0	NC*
Total	0.27	0	NC*

<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.15	0	NC*	Male	0.07	0	NC*
Female	0.03	0	NC*				
Total	0.18	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.21	0	NC*	Male	0.05	0	NC*
Female	0.13	0	NC*	Female	0.12	0	NC*
Total	0.33	0	NC*	Total	0.17	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.10	0	NC*				
Female	0.03	0	NC*	Female	0.45	0	NC*
Total	0.13	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	1.43	1	NC*	Male	8.97	3	NC*
Female	0.94	0	NC*	Female	6.85	4	NC*
Total	2.37	1	NC*	Total	15.82	7	44 #–

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

– indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Plainville

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	4.38	7	160	Male	3.18	3	NC*
Female	1.87	2	NC*	Female	2.59	3	NC*
Total	6.25	9	144	Total	5.77	6	104
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.47	4	NC*	Male	0.88	1	NC*
Female	1.21	2	NC*	Female	0.84	1	NC*
Total	2.68	6	224	Total	1.72	2	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.21	1	NC*	Male	3.81	3	NC*
Female	30.48	22	72	Female	3.60	3	NC*
Total	30.69	23	75	Total	7.41	6	81
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.79	2	NC*	Male	2.97	0	NC*
				Female	1.50	1	NC*
				Total	4.47	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	10.97	10	91				
Female	11.72	10	85	Female	3.57	1	NC*
Total	22.69	20	88				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			

Male	1.65	2	NC*
Female	0.57	0	NC*
Total	2.22	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	0.80	1	NC*
Female	0.62	2	NC*
Total	1.41	3	NC*
<b><u>Kidney and Renal Pelvis</u></b>			
Male	2.74	2	NC*
Female	1.82	1	NC*
Total	4.56	3	NC*
<b><u>Larynx</u></b>			
Male	1.56	1	NC*
Female	0.42	0	NC*
Total	1.98	1	NC*
<b><u>Leukemia</u></b>			
Male	2.19	0	NC*
Female	1.84	2	NC*
Total	4.04	2	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	1.06	1	NC*
Female	0.47	0	NC*
Total	1.54	1	NC*
<b><u>Lung and Bronchus</u></b>			
Male	14.13	26	184 ~+
Female	12.36	14	113
Total	26.49	40	151 #+

Male	1.89	0	NC*
Female	2.16	1	NC*
Total	4.04	1	NC*
<b><u>Prostate</u></b>			
Male	27.82	22	79
<b><u>Stomach</u></b>			
Male	1.88	0	NC*
Female	1.28	0	NC*
Total	3.17	0	NC*
<b><u>Testis</u></b>			
Male	1.28	1	NC*
<b><u>Thyroid</u></b>			
Male	0.69	1	NC*
Female	1.84	3	NC*
Total	2.53	4	NC*
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	5.83	4	NC*
<b><u>All Sites / Types</u></b>			
Male	91.81	88	96
Female	95.28	84	88
Total	187.09	172	92

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Plymouth

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	28.50	38	133	Male	20.20	30	148 #+
Female	11.29	17	151	Female	15.83	11	69
Total	39.79	55	138 #+	Total	36.04	41	114
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	9.28	11	119	Male	5.70	10	175
Female	7.51	9	120	Female	5.12	9	176
Total	16.79	20	119	Total	10.83	19	175 #+
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	1.37	0	NC*	Male	24.27	19	78

Female	186.62	183	98
Total	188.00	183	97

#### Cervix Uteri

Female	10.89	16	147
--------	-------	----	-----

#### Colon / Rectum

Male	70.92	80	113
Female	71.05	65	91
Total	141.97	145	102

#### Esophagus

Male	10.57	8	76
Female	3.43	2	NC*
Total	14.00	10	71

#### Hodgkin's Disease (Hodgkin Lymphoma)

Male	4.82	8	166
Female	3.75	3	NC*
Total	8.57	11	128

#### Kidney and Renal Pelvis

Male	17.67	21	119
Female	11.05	12	109
Total	28.72	33	115

#### Larynx

Male	10.00	8	80
Female	2.52	4	NC*
Total	12.52	12	96

#### Leukemia

Male	14.19	12	85
Female	11.42	13	114
Total	25.61	25	98

#### Liver and Intrahepatic Bile Ducts

Male	6.80	5	73
Female	2.86	1	NC*
Total	9.66	6	62

#### Lung and Bronchus

Male	90.44	101	112
Female	74.52	87	117
Total	164.97	188	114

Female	21.84	28	128
Total	46.11	47	102

#### Oral Cavity and Pharynx

Male	19.02	24	126
Female	9.16	13	142
Total	28.18	37	131

#### Ovary

Female	21.83	15	69
--------	-------	----	----

#### Pancreas

Male	12.16	9	74
Female	12.94	12	93
Total	25.10	21	84

#### Prostate

Male	176.64	183	104
------	--------	-----	-----

#### Stomach

Male	12.24	14	114
Female	7.74	4	NC*
Total	19.98	18	90

#### Testis

Male	7.40	10	135
------	------	----	-----

#### Thyroid

Male	4.20	3	NC*
Female	11.22	11	98
Total	15.42	14	91

#### Uteri, Corpus and Uterus, NOS

Female	35.74	31	87
--------	-------	----	----

#### All Sites / Types

Male	586.47	634	108
Female	580.62	584	101
Total	1167.10	1218	104

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Plympton

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	1.27	2	NC*
Female	0.47	0	NC*
Total	1.74	2	NC*
<b><u>Brain and Other Central Nervous System</u></b>			
Male	0.50	0	NC*
Female	0.37	1	NC*
Total	0.87	1	NC*
<b><u>Breast</u></b>			
Male	0.07	0	NC*
Female	9.72	8	82
Total	9.79	8	82
<b><u>Cervix Uteri</u></b>			
Female	0.57	0	NC*
<b><u>Colon / Rectum</u></b>			
Male	3.26	4	NC*
Female	2.90	3	NC*
Total	6.16	7	114
<b><u>Esophagus</u></b>			
Male	0.56	0	NC*
Female	0.14	0	NC*
Total	0.70	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	0.25	0	NC*
Female	0.18	0	NC*
Total	0.43	0	NC*
<b><u>Kidney and Renal Pelvis</u></b>			
Male	0.94	1	NC*
Female	0.54	0	NC*
Total	1.48	1	NC*
<b><u>Larynx</u></b>			
Male	0.56	0	NC*
Female	0.13	0	NC*
Total	0.69	0	NC*
<b><u>Leukemia</u></b>			
Male	0.69	1	NC*
Female	0.52	0	NC*
Total	1.21	1	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	0.36	0	NC*
Female	0.12	0	NC*
Total	0.49	0	NC*
<b><u>Lung and Bronchus</u></b>			
Male	4.51	1	NC*
Female	3.64	1	NC*
Total	8.15	2	NC*

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	1.05	1	NC*
Female	0.79	0	NC*
Total	1.85	1	NC*
<b><u>Multiple Myeloma</u></b>			
Male	0.28	0	NC*
Female	0.24	1	NC*
Total	0.52	1	NC*
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	1.22	0	NC*
Female	1.00	2	NC*
Total	2.21	2	NC*
<b><u>Oral Cavity and Pharynx</u></b>			
Male	1.06	0	NC*
Female	0.45	0	NC*
Total	1.51	0	NC*
<b><u>Ovary</u></b>			
Female	1.13	1	NC*
<b><u>Pancreas</u></b>			
Male	0.59	0	NC*
Female	0.54	0	NC*
Total	1.14	0	NC*
<b><u>Prostate</u></b>			
Male	9.24	4	NC*
<b><u>Stomach</u></b>			
Male	0.57	0	NC*
Female	0.31	0	NC*
Total	0.88	0	NC*
<b><u>Testis</u></b>			
Male	0.37	0	NC*
<b><u>Thyroid</u></b>			
Male	0.24	0	NC*
Female	0.58	0	NC*
Total	0.81	0	NC*
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	1.91	1	NC*
<b><u>All Sites / Types</u></b>			
Male	29.45	17	58 #–
Female	28.07	20	71
Total	57.52	37	64 ~–

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Princeton

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.90	4	NC*	Male	1.47	1	NC*
Female	0.59	1	NC*	Female	1.03	2	NC*
Total	2.49	5	200	Total	2.50	3	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.70	0	NC*	Male	0.41	0	NC*
Female	0.48	1	NC*	Female	0.30	0	NC*
Total	1.18	1	NC*	Total	0.71	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.10	0	NC*	Male	1.72	2	NC*
Female	12.50	11	88	Female	1.28	0	NC*
Total	12.59	11	87	Total	2.99	2	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.74	2	NC*	Male	1.48	0	NC*
				Female	0.58	1	NC*
				Total	2.06	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	4.85	5	103	Female	1.46	0	NC*
Female	3.68	2	NC*				
Total	8.52	7	82				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.80	0	NC*	Male	0.86	0	NC*
Female	0.18	0	NC*	Female	0.69	1	NC*
Total	0.98	0	NC*	Total	1.55	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.33	0	NC*	Male	13.49	9	67
Female	0.24	0	NC*				
Total	0.57	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.33	0	NC*	Male	0.83	1	NC*
Female	0.69	0	NC*	Female	0.39	0	NC*
Total	2.02	0	NC*	Total	1.23	1	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.79	0	NC*	Male	0.47	0	NC*
Female	0.17	0	NC*				
Total	0.96	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.99	2	NC*	Male	0.31	0	NC*
Female	0.68	0	NC*	Female	0.77	0	NC*
Total	1.67	2	NC*	Total	1.08	0	NC*

**Liver and Intrahepatic Bile Ducts**

Male	0.52	0	NC*
Female	0.16	0	NC*
Total	0.67	0	NC*

**Lung and Bronchus**

Male	6.63	4	NC*
Female	4.59	0	NC*
Total	11.22	4	NC*

**Uteri, Corpus and Uterus, NOS**

Female	2.44	2	NC*
--------	------	---	-----

**All Sites / Types**

Male	42.69	30	70
Female	35.95	23	64 #-
Total	78.64	53	67 ~-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Provincetown**

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	3.57	4	NC*	Male	2.12	1	NC*
Female	1.32	2	NC*	Female	1.50	1	NC*
Total	4.88	6	123	Total	3.62	2	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.85	0	NC*	Male	0.67	0	NC*
Female	0.66	0	NC*	Female	0.57	1	NC*
Total	1.51	0	NC*	Total	1.24	1	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.16	0	NC*	Male	2.56	5	195
Female	18.82	17	90	Female	2.30	1	NC*
Total	18.98	17	90	Total	4.87	6	123
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.93	1	NC*	Male	2.01	1	NC*
				Female	0.96	0	NC*
				Total	2.98	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	8.76	8	91	Female	2.13	2	NC*
Female	8.26	10	121				
Total	17.03	18	106				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.22	3	NC*	Male	1.46	0	NC*
Female	0.40	0	NC*	Female	1.51	1	NC*
Total	1.62	3	NC*	Total	2.97	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.36	2	NC*	Male	21.49	20	93
Female	0.28	0	NC*				
Total	0.64	2	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			

Male	1.93	3	NC*	Male	1.48	3	NC*
Female	1.16	0	NC*	Female	0.90	2	NC*
Total	3.09	3	NC*	Total	2.38	5	210
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.12	1	NC*	Male	0.48	1	NC*
Female	0.26	1	NC*				
Total	1.38	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.47	4	NC*	Male	0.36	0	NC*
Female	1.12	1	NC*	Female	0.89	1	NC*
Total	2.59	5	193	Total	1.25	1	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.75	0	NC*				
Female	0.32	0	NC*	Female	3.67	4	NC*
Total	1.07	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	10.96	11	100	Male	68.29	91	133 #+
Female	8.11	14	173	Female	60.70	64	105
Total	19.07	25	131	Total	128.99	155	120 #+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Quincy

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	52.53	69	131 #+	Male	35.20	38	108
Female	25.53	35	137	Female	32.15	41	128
Total	78.07	104	133 ~+	Total	67.35	79	117
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	15.70	22	140	Male	10.10	8	79
Female	14.84	19	128	Female	11.03	11	100
Total	30.54	41	134	Total	21.13	19	90
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	2.44	3	NC*	Male	42.79	59	138 #+
Female	374.25	379	101	Female	47.05	38	81
Total	376.69	382	101	Total	89.84	97	108
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
				Male	31.77	38	120
Female	21.75	29	133	Female	18.99	12	63
				Total	50.76	50	98
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	130.27	162	124 ~+				

Female	161.03	181	112
Total	291.30	343	118 ~+

#### Esophagus

Male	18.30	24	131
Female	7.83	8	102
Total	26.13	32	122

#### Hodgkin's Disease (Hodgkin Lymphoma)

Male	8.55	6	70
Female	7.65	7	92
Total	16.19	13	80

#### Kidney and Renal Pelvis

Male	30.31	27	89
Female	23.11	19	82
Total	53.42	46	86

#### Larynx

Male	17.05	24	141
Female	5.08	9	177
Total	22.13	33	149 #+

#### Leukemia

Male	24.69	31	126
Female	23.35	21	90
Total	48.04	52	108

#### Liver and Intrahepatic Bile Ducts

Male	11.75	23	196 ~+
Female	6.30	5	79
Total	18.05	28	155 #+

#### Lung and Bronchus

Male	163.73	195	119 #+
Female	158.79	207	130 ^+
Total	322.52	402	125 ^+

Female	43.78	41	94
--------	-------	----	----

#### Pancreas

Male	21.78	26	119
Female	29.34	30	102
Total	51.11	56	110

#### Prostate

Male	317.00	347	109
------	--------	-----	-----

#### Stomach

Male	22.03	28	127
Female	17.67	14	79
Total	39.70	42	106

#### Testis

Male	13.94	16	115
------	-------	----	-----

#### Thyroid

Male	7.23	8	111
Female	22.28	17	76
Total	29.51	25	85

#### Uteri, Corpus and Uterus, NOS

Female	70.93	83	117
--------	-------	----	-----

#### All Sites / Types

Male	1049.47	1243	118 ^+
Female	1214.88	1308	108 ~+
Total	2264.35	2551	113 ^+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Randolph

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<u>Bladder, Urinary</u>			
Male	20.68	16	77
Female	8.45	15	177
Total	29.13	31	106

#### Brain and Other Central Nervous System

Male	6.25	2	NC*
Female	5.29	6	113

#### Melanoma of Skin

Male	13.95	11	79
Female	11.28	14	124
Total	25.23	25	99

#### Multiple Myeloma

Male	4.07	4	NC*
Female	3.82	3	NC*

Total	11.54	8	69	Total	7.88	7	89
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.98	1	NC*	Male	16.80	25	149
Female	135.86	110	81 #-	Female	16.11	13	81
Total	136.85	111	81 #-	Total	32.90	38	115
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	7.65	2	NC*	Male	13.09	17	130
				Female	6.73	6	89
				Total	19.82	23	116
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	51.59	70	136 #+	Female	15.80	17	108
Female	52.88	49	93				
Total	104.47	119	114				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	7.52	3	NC*	Male	8.73	10	115
Female	2.58	3	NC*	Female	9.80	6	61
Total	10.10	6	59	Total	18.53	16	86
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	3.15	0	NC*	Male	130.91	141	108
Female	2.55	1	NC*				
Total	5.70	1	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	12.34	7	57	Male	8.70	10	115
Female	8.21	10	122	Female	5.73	4	NC*
Total	20.55	17	83	Total	14.43	14	97
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	7.09	6	85	Male	4.81	6	125
Female	1.90	2	NC*				
Total	9.00	8	89				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	9.75	15	154	Male	2.80	5	179
Female	8.08	10	124	Female	7.74	10	129
Total	17.82	25	140	Total	10.54	15	142
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	4.80	3	NC*	Female	26.33	22	84
Female	2.14	4	NC*				
Total	6.94	7	101				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	66.44	73	110	Male	422.61	450	106
Female	56.67	79	139 ~+	Female	426.30	423	99
Total	123.10	152	123 #+	Total	848.91	873	103

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

# Raynham

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	6.81	3	NC*	Male	4.80	12	250 ~+
Female	2.49	3	NC*	Female	3.65	4	NC*
Total	9.30	6	65	Total	8.45	16	189 #+
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.19	4	NC*	Male	1.38	1	NC*
Female	1.75	1	NC*	Female	1.19	2	NC*
Total	3.93	5	127	Total	2.58	3	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.33	0	NC*	Male	5.71	8	140
Female	44.92	44	98	Female	5.01	9	180
Total	45.25	44	97	Total	10.72	17	159
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	2.52	3	NC*	Male	4.63	5	108
				Female	2.16	1	NC*
				Total	6.79	6	88
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	17.09	28	164 #+	Female	5.22	6	115
Female	15.51	23	148				
Total	32.60	51	156 ~+				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	2.60	0	NC*	Male	2.94	3	NC*
Female	0.75	1	NC*	Female	2.91	2	NC*
Total	3.36	1	NC*	Total	5.85	5	86
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.06	2	NC*	Male	44.59	48	108
Female	0.81	3	NC*				
Total	1.87	5	267				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	4.30	4	NC*	Male	2.90	3	NC*
Female	2.63	3	NC*	Female	1.65	0	NC*
Total	6.93	7	101	Total	4.55	3	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.49	0	NC*	Male	1.56	3	NC*
Female	0.64	1	NC*				
Total	3.13	1	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	3.32	4	NC*	Male	0.97	1	NC*
Female	2.54	2	NC*	Female	2.54	1	NC*
Total	5.86	6	102	Total	3.52	2	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.66	3	NC*	Female	8.85	8	90
Female	0.65	0	NC*				
Total	2.31	3	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	22.43	36	161 #+	Male	143.17	184	129 ~+
Female	18.21	18	99	Female	135.80	140	103
Total	40.64	54	133	Total	278.97	324	116 ~+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Reading

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	15.58	12	77	Male	10.67	22	206 ~+
Female	5.96	7	118	Female	8.19	14	171
Total	21.54	19	88	Total	18.86	36	191 ^+
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	4.80	5	104	Male	3.09	2	NC*
Female	3.88	2	NC*	Female	2.74	4	NC*
Total	8.68	7	81	Total	5.83	6	103
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.75	0	NC*	Male	12.80	12	94
Female	99.63	120	120	Female	11.53	14	121
Total	100.38	120	120	Total	24.33	26	107
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	5.56	6	108	Male	10.18	9	88
				Female	4.88	4	NC*
				Total	15.06	13	86
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	38.93	31	80	Female	11.57	15	130
Female	37.20	39	105				
Total	76.13	70	92				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	5.80	8	138	Male	6.66	6	90
Female	1.82	1	NC*	Female	6.92	6	87
Total	7.61	9	118	Total	13.58	12	88
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	2.37	2	NC*	Male	99.80	79	79 #-
Female	1.83	2	NC*				
Total	4.21	4	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	9.47	4	NC*	Male	6.63	9	136
Female	5.95	6	101	Female	4.01	3	NC*
Total	15.42	10	65	Total	10.65	12	113
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	5.48	1	NC*	Male	3.54	2	NC*
Female	1.40	0	NC*				
Total	6.88	1	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			

Male	7.42	5	67
Female	5.86	2	NC*
Total	13.28	7	53

#### Liver and Intrahepatic Bile Ducts

Male	3.69	2	NC*
Female	1.52	0	NC*
Total	5.21	2	NC*

#### Lung and Bronchus

Male	50.29	46	91
Female	40.96	27	66 #-
Total	91.26	73	80

Male	2.15	4	NC*
Female	5.62	5	89
Total	7.77	9	116

#### Uteri, Corpus and Uterus, NOS

Female	19.43	26	134
--------	-------	----	-----

#### All Sites / Types

Male	321.40	279	87 #-
Female	308.31	326	106
Total	629.71	605	96

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rehoboth

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	5.83	7	120
Female	2.01	0	NC*
Total	7.84	7	89

#### **Brain and Other Central Nervous System**

Male	2.01	0	NC*
Female	1.50	0	NC*
Total	3.51	0	NC*

#### **Breast**

Male	0.30	0	NC*
Female	38.79	48	124
Total	39.08	48	123

#### **Cervix Uteri**

Female	2.27	2	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	14.72	5	34 ~-
Female	12.52	9	72
Total	27.24	14	51 ~-

#### **Esophagus**

Male	2.37	2	NC*
Female	0.61	0	NC*
Total	2.98	2	NC*

#### **Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.97	3	NC*
------	------	---	-----

#### **Melanoma of Skin**

Male	4.38	3	NC*
Female	3.20	2	NC*
Total	7.59	5	66

#### **Multiple Myeloma**

Male	1.23	0	NC*
Female	0.98	2	NC*
Total	2.20	2	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	5.13	3	NC*
Female	4.15	4	NC*
Total	9.28	7	75

#### **Oral Cavity and Pharynx**

Male	4.35	3	NC*
Female	1.83	0	NC*
Total	6.18	3	NC*

#### **Ovary**

Female	4.52	5	111
--------	------	---	-----

#### **Pancreas**

Male	2.60	1	NC*
Female	2.34	0	NC*
Total	4.94	1	NC*

#### **Prostate**

Male	39.47	30	76
------	-------	----	----

Female	0.73	1	NC*				
Total	1.70	4	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	3.92	3	NC*	Male	2.55	1	NC*
Female	2.20	1	NC*	Female	1.35	2	NC*
Total	6.12	4	NC*	Total	3.90	3	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.30	1	NC*	Male	1.40	1	NC*
Female	0.54	0	NC*				
Total	2.83	1	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	2.94	2	NC*	Male	0.92	1	NC*
Female	2.16	4	NC*	Female	2.32	1	NC*
Total	5.11	6	118	Total	3.24	2	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.52	2	NC*	Female	7.56	7	93
Female	0.53	0	NC*				
Total	2.04	2	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	19.62	12	61	Male	126.73	82	65 ^-
Female	14.87	13	87	Female	114.65	109	95
Total	34.49	25	72	Total	241.39	191	79 ^-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Revere

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	30.69	36	117	Male	19.01	17	89
Female	11.98	12	100	Female	14.67	12	82
Total	42.67	48	112	Total	33.68	29	86
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	8.29	14	169	Male	5.76	11	191
Female	7.00	5	71	Female	5.23	3	NC*
Total	15.29	19	124	Total	10.99	14	127
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	1.38	3	NC*	Male	23.41	28	120
Female	174.87	204	117 #+	Female	22.04	31	141
Total	176.25	207	117 #+	Total	45.45	59	130
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	9.68	12	124	Male	17.13	21	123
				Female	8.91	9	101

				Total	26.04	30	115
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	75.32	95	126 #+				
Female	75.56	84	111	Female	20.37	26	128
Total	150.88	179	119 #+				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	10.18	10	98	Male	12.41	10	81
Female	3.68	4	NC*	Female	13.81	27	196 ~+
Total	13.86	14	101	Total	26.22	37	141
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	4.20	9	214	Male	177.94	173	97
Female	3.38	7	207				
Total	7.58	16	211 #+				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	16.69	19	114	Male	12.70	23	181 #+
Female	10.92	18	165	Female	8.20	12	146
Total	27.61	37	134	Total	20.90	35	167 ~+
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	9.32	17	182 #+	Male	6.42	8	125
Female	2.43	7	288 #+				
Total	11.75	24	204 ~+				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	13.86	7	51	Male	3.58	6	168
Female	11.03	19	172 #+	Female	9.79	5	51
Total	24.88	26	104	Total	13.37	11	82
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	6.46	11	170				
Female	2.98	2	NC*	Female	33.62	41	122
Total	9.44	13	138				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	92.78	134	144 ^+	Male	588.35	697	118 ^+
Female	75.78	112	148 ^+	Female	568.96	706	124 ^+
Total	168.56	246	146 ^+	Total	1157.30	1403	121 ^+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Richmond

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.59	0	NC*	Male	1.03	1	NC*
Female	0.51	2	NC*	Female	0.70	0	NC*
Total	2.09	2	NC*	Total	1.73	1	NC*

**Brain and Other Central Nervous System**

Male	0.44	0	NC*
Female	0.33	0	NC*
Total	0.77	0	NC*

**Breast**

Male	0.08	0	NC*
Female	8.96	9	100
Total	9.03	9	100

**Cervix Uteri**

Female	0.47	0	NC*
--------	------	---	-----

**Colon / Rectum**

Male	3.93	2	NC*
Female	3.16	2	NC*
Total	7.09	4	NC*

**Esophagus**

Male	0.58	1	NC*
Female	0.15	0	NC*
Total	0.74	1	NC*

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.18	0	NC*
Female	0.14	1	NC*
Total	0.33	1	NC*

**Kidney and Renal Pelvis**

Male	0.94	0	NC*
Female	0.53	0	NC*
Total	1.46	0	NC*

**Larynx**

Male	0.55	0	NC*
Female	0.13	0	NC*
Total	0.68	0	NC*

**Leukemia**

Male	0.71	0	NC*
Female	0.49	0	NC*
Total	1.20	0	NC*

**Liver and Intrahepatic Bile Ducts**

Male	0.36	0	NC*
Female	0.13	1	NC*
Total	0.49	1	NC*

**Lung and Bronchus**

Male	5.05	1	NC*
Female	3.67	0	NC*
Total	8.72	1	NC*

**Multiple Myeloma**

Male	0.31	0	NC*
Female	0.24	0	NC*
Total	0.56	0	NC*

**Non-Hodgkin(s) Lymphoma**

Male	1.22	1	NC*
Female	0.99	2	NC*
Total	2.21	3	NC*

**Oral Cavity and Pharynx**

Male	1.01	3	NC*
Female	0.43	0	NC*
Total	1.44	3	NC*

**Ovary**

Female	1.03	1	NC*
--------	------	---	-----

**Pancreas**

Male	0.67	0	NC*
Female	0.59	0	NC*
Total	1.26	0	NC*

**Prostate**

Male	10.00	5	50
------	-------	---	----

**Stomach**

Male	0.67	0	NC*
Female	0.33	0	NC*
Total	1.00	0	NC*

**Testis**

Male	0.24	0	NC*
------	------	---	-----

**Thyroid**

Male	0.19	0	NC*
Female	0.46	0	NC*
Total	0.65	0	NC*

**Uteri, Corpus and Uterus, NOS**

Female	1.78	0	NC*
--------	------	---	-----

**All Sites / Types**

Male	31.80	14	44 ^-
Female	27.07	18	66
Total	58.87	32	54 ^-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rochester

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	2.76	5	181	Male	2.02	3	NC*
Female	0.87	2	NC*	Female	1.42	1	NC*
Total	3.63	7	193	Total	3.44	4	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.91	2	NC*	Male	0.57	0	NC*
Female	0.66	2	NC*	Female	0.43	0	NC*
Total	1.57	4	NC*	Total	1.00	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.14	0	NC*	Male	2.39	2	NC*
Female	17.15	12	70	Female	1.80	1	NC*
Total	17.28	12	69	Total	4.19	3	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.01	1	NC*	Male	2.01	0	NC*
				Female	0.80	1	NC*
				Total	2.81	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	6.91	2	NC*	Female	1.99	5	251
Female	5.41	6	111				
Total	12.31	8	65				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.10	0	NC*	Male	1.22	0	NC*
Female	0.26	0	NC*	Female	1.00	0	NC*
Total	1.36	0	NC*	Total	2.22	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.43	0	NC*	Male	17.88	12	67
Female	0.32	0	NC*				
Total	0.75	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.81	1	NC*	Male	1.22	0	NC*
Female	0.96	0	NC*	Female	0.58	1	NC*
Total	2.76	1	NC*	Total	1.80	1	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.05	2	NC*	Male	0.61	0	NC*
Female	0.23	0	NC*				
Total	1.28	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.37	1	NC*	Male	0.42	1	NC*
Female	0.95	0	NC*	Female	1.04	1	NC*
Total	2.32	1	NC*	Total	1.45	2	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.70	0	NC*	Female	3.33	2	NC*
Female	0.23	0	NC*				
Total	0.92	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	8.96	9	100	Male	58.32	43	74 #~

Female	6.39	5	78	Female	50.19	47	94
Total	15.35	14	91	Total	108.50	90	83

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rockland

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	9.47	14	148	Male	6.64	18	271 ^+
Female	3.87	3	NC*	Female	5.40	11	204 #+
Total	13.34	17	127	Total	12.03	29	241 ^+
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	3.11	2	NC*	Male	1.87	1	NC*
Female	2.60	3	NC*	Female	1.76	2	NC*
Total	5.72	5	87	Total	3.63	3	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.46	0	NC*	Male	8.02	4	NC*
Female	63.63	69	108	Female	7.57	6	79
Total	64.09	69	108	Total	15.59	10	64
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	3.74	1	NC*	Male	6.16	5	81
				Female	3.14	3	NC*
				Total	9.30	8	86
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	23.73	27	114	Female	7.48	8	107
Female	24.25	24	99				
Total	47.98	51	106				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	3.49	5	143	Male	4.03	6	149
Female	1.18	0	NC*	Female	4.50	5	111
Total	4.67	5	107	Total	8.53	11	129
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.65	2	NC*	Male	60.75	66	109
Female	1.32	0	NC*				
Total	2.97	2	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	5.80	5	86	Male	4.00	6	150
Female	3.84	3	NC*	Female	2.63	0	NC*
Total	9.64	8	83	Total	6.63	6	91
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	3.31	8	241 #+	Male	2.61	1	NC*
Female	0.89	2	NC*				

Total	4.20	10	238 #+
<b><u>Leukemia</u></b>			
Male	4.71	3	NC*
Female	3.88	6	155
Total	8.59	9	105

**Liver and Intrahepatic Bile Ducts**

Male	2.26	2	NC*
Female	0.99	1	NC*
Total	3.25	3	NC*

**Lung and Bronchus**

Male	30.79	46	149 #+
Female	26.36	50	190 ^+
Total	57.15	96	168 ^+

**Thyroid**

Male	1.40	2	NC*
Female	3.86	6	155
Total	5.26	8	152

**Uteri, Corpus and Uterus, NOS**

Female	12.26	8	65
--------	-------	---	----

**All Sites / Types**

Male	197.56	233	118 #+
Female	199.43	222	111
Total	396.99	455	115 ~+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rockport

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>			
Male	7.03	4	NC*
Female	3.06	4	NC*
Total	10.09	8	79

**Brain and Other Central Nervous System**

Male	1.76	0	NC*
Female	1.59	1	NC*
Total	3.35	1	NC*

**Breast**

Male	0.32	3	NC*
Female	42.91	39	91
Total	43.23	42	97

**Cervix Uteri**

Female	2.16	1	NC*
--------	------	---	-----

**Colon / Rectum**

Male	17.19	12	70
Female	19.25	12	62
Total	36.44	24	66 #-

**Esophagus**

Male	2.40	2	NC*
Female	0.94	0	NC*
Total	3.34	2	NC*

**Melanoma of Skin**

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
Male	4.27	3	NC*
Female	3.46	5	144
Total	7.74	8	103

**Multiple Myeloma**

Male	1.33	0	NC*
Female	1.31	0	NC*
Total	2.65	0	NC*

**Non-Hodgkin('s) Lymphoma**

Male	5.19	2	NC*
Female	5.36	7	131
Total	10.55	9	85

**Oral Cavity and Pharynx**

Male	4.05	3	NC*
Female	2.22	2	NC*
Total	6.26	5	80

**Ovary**

Female	4.90	4	NC*
--------	------	---	-----

**Pancreas**

Male	2.88	2	NC*
Female	3.50	2	NC*
Total	6.39	4	NC*

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.77	1	NC*
Female	0.69	0	NC*
Total	1.46	1	NC*

**Kidney and Renal Pelvis**

Male	3.85	3	NC*
Female	2.68	2	NC*
Total	6.53	5	77

**Larynx**

Male	2.20	1	NC*
Female	0.60	1	NC*
Total	2.79	2	NC*

**Leukemia**

Male	3.02	6	198
Female	2.69	5	186
Total	5.71	11	192

**Liver and Intrahepatic Bile Ducts**

Male	1.49	0	NC*
Female	0.75	1	NC*
Total	2.24	1	NC*

**Lung and Bronchus**

Male	21.16	10	47 #--
Female	18.55	13	70
Total	39.71	23	58 ~--

**Prostate**

Male	41.07	27	66 #--
------	-------	----	--------

**Stomach**

Male	2.95	1	NC*
Female	2.11	6	284 #+
Total	5.06	7	138

**Testis**

Male	1.03	0	NC*
------	------	---	-----

**Thyroid**

Male	0.75	1	NC*
Female	2.09	2	NC*
Total	2.84	3	NC*

**Uteri, Corpus and Uterus, NOS**

Female	8.32	14	168
--------	------	----	-----

**All Sites / Types**

Male	133.76	88	66 ^--
Female	139.98	134	96
Total	273.74	222	81 ~--

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Rowe**

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.40	0	NC*	Male	0.24	0	NC*
Female	0.12	0	NC*	Female	0.15	1	NC*
Total	0.52	0	NC*	Total	0.38	1	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.09	0	NC*	Male	0.07	0	NC*
Female	0.07	0	NC*	Female	0.05	1	NC*
Total	0.16	0	NC*	Total	0.13	1	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.02	0	NC*	Male	0.29	0	NC*
Female	1.95	2	NC*	Female	0.22	0	NC*
Total	1.96	2	NC*	Total	0.51	0	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			

Female	0.09	0	NC*	Male	0.23	0	NC*
				Female	0.10	0	NC*
				Total	0.33	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	0.96	0	NC*	Female	0.22	0	NC*
Female	0.73	0	NC*				
Total	1.70	0	NC*				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.14	0	NC*	Male	0.16	0	NC*
Female	0.04	0	NC*	Female	0.14	1	NC*
Total	0.17	0	NC*	Total	0.30	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.04	0	NC*	Male	2.27	1	NC*
Female	0.03	0	NC*				
Total	0.06	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.21	0	NC*	Male	0.17	0	NC*
Female	0.12	0	NC*	Female	0.08	0	NC*
Total	0.33	0	NC*	Total	0.25	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.12	0	NC*	Male	0.04	0	NC*
Female	0.03	0	NC*				
Total	0.15	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.16	0	NC*	Male	0.04	0	NC*
Female	0.11	0	NC*	Female	0.09	0	NC*
Total	0.28	0	NC*	Total	0.13	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.08	0	NC*	Female	0.39	0	NC*
Female	0.03	0	NC*				
Total	0.11	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	1.16	1	NC*	Male	7.40	2	NC*
Female	0.83	0	NC*	Female	6.00	5	83
Total	1.99	1	NC*	Total	13.41	7	52

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Rowley

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	2.64	0	NC*	Male	1.98	3	NC*

Female	0.88	0	NC*	Female	1.48	2	NC*
Total	3.52	0	NC*	Total	3.46	5	144
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.93	1	NC*	Male	0.54	0	NC*
Female	0.70	0	NC*	Female	0.42	0	NC*
Total	1.63	1	NC*	Total	0.96	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.13	0	NC*	Male	2.36	3	NC*
Female	17.04	13	76	Female	1.85	2	NC*
Total	17.17	13	76	Total	4.22	5	119
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.08	1	NC*	Male	1.90	1	NC*
<b><u>Colon / Rectum</u></b>				Female	0.80	0	NC*
Male	6.62	5	76	Total	2.70	1	NC*
Female	5.52	10	181	<b><u>Ovary</u></b>			
Total	12.14	15	124	Female	2.02	4	NC*
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.03	1	NC*	Male	1.16	0	NC*
Female	0.27	0	NC*	Female	1.01	0	NC*
Total	1.30	1	NC*	Total	2.17	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.49	0	NC*	Male	16.89	17	101
Female	0.38	0	NC*	<b><u>Stomach</u></b>			
Total	0.87	0	NC*	Male	1.16	1	NC*
<b><u>Kidney and Renal Pelvis</u></b>				Female	0.60	1	NC*
Male	1.72	0	NC*	Total	1.76	2	NC*
Female	0.96	0	NC*	<b><u>Testis</u></b>			
Total	2.68	0	NC*	Male	0.75	4	NC*
<b><u>Larynx</u></b>				<b><u>Thyroid</u></b>			
Male	0.98	0	NC*	Male	0.43	0	NC*
Female	0.23	0	NC*	Female	1.15	1	NC*
Total	1.21	0	NC*	Total	1.58	1	NC*
<b><u>Leukemia</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.37	3	NC*	Female	3.24	1	NC*
Female	1.00	3	NC*	<b><u>All Sites / Types</u></b>			
Total	2.37	6	254	Male	56.09	55	98
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				Female	50.64	46	91
Male	0.66	0	NC*	Total	106.73	101	95
Female	0.23	0	NC*				
Total	0.89	0	NC*				
<b><u>Lung and Bronchus</u></b>							
Male	8.53	11	129				
Female	6.31	5	79				
Total	14.84	16	108				

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Royalston

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.81	1	NC*	Male	0.55	0	NC*
Female	0.25	0	NC*	Female	0.35	1	NC*
Total	1.06	1	NC*	Total	0.90	1	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.24	0	NC*	Male	0.16	0	NC*
Female	0.17	0	NC*	Female	0.12	0	NC*
Total	0.41	0	NC*	Total	0.28	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.04	0	NC*	Male	0.65	0	NC*
Female	4.21	3	NC*	Female	0.49	1	NC*
Total	4.25	3	NC*	Total	1.14	1	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.24	0	NC*	Male	0.53	0	NC*
				Female	0.21	0	NC*
				Total	0.73	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	2.00	5	250	Female	0.49	1	NC*
Female	1.59	0	NC*				
Total	3.58	5	140				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.30	0	NC*	Male	0.34	1	NC*
Female	0.08	0	NC*	Female	0.29	0	NC*
Total	0.37	0	NC*	Total	0.63	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.11	0	NC*	Male	5.01	1	NC*
Female	0.08	0	NC*				
Total	0.20	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.49	0	NC*	Male	0.34	0	NC*
Female	0.25	1	NC*	Female	0.17	0	NC*
Total	0.74	1	NC*	Total	0.51	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.28	0	NC*	Male	0.16	0	NC*
Female	0.06	0	NC*				
Total	0.34	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.38	0	NC*	Male	0.11	0	NC*
Female	0.25	0	NC*	Female	0.25	0	NC*
Total	0.63	0	NC*	Total	0.35	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.19	0	NC*				
Female	0.06	0	NC*	Female	0.81	1	NC*

Total	0.25	0	NC*
<b><u>Lung and Bronchus</u></b>			
Male	2.55	0	NC*
Female	1.70	0	NC*
Total	4.25	0	NC*

#### **All Sites / Types**

Male	16.31	8	49 #-
Female	13.07	8	61
Total	29.38	16	54 #-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## **Russell**

**Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.07	0	NC*	Male	0.75	0	NC*
Female	0.34	0	NC*	Female	0.53	0	NC*
Total	1.41	0	NC*	Total	1.28	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.33	0	NC*	Male	0.21	0	NC*
Female	0.25	2	NC*	Female	0.16	0	NC*
Total	0.58	2	NC*	Total	0.37	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.05	0	NC*	Male	0.89	0	NC*
Female	6.21	3	NC*	Female	0.69	1	NC*
Total	6.26	3	NC*	Total	1.58	1	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.38	0	NC*	Male	0.71	0	NC*
				Female	0.30	0	NC*
				Total	1.01	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	2.67	4	NC*	Female	0.73	0	NC*
Female	2.11	0	NC*				
Total	4.79	4	NC*				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.40	0	NC*	Male	0.46	1	NC*
Female	0.10	0	NC*	Female	0.39	1	NC*
Total	0.50	0	NC*	Total	0.85	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.17	0	NC*	Male	6.71	8	119
Female	0.13	0	NC*				
Total	0.30	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.66	0	NC*	Male	0.46	0	NC*
Female	0.36	3	NC*	Female	0.23	0	NC*
Total	1.01	3	NC*	Total	0.69	0	NC*

**Larynx**

Male	0.38	1	NC*
Female	0.08	0	NC*
Total	0.46	1	NC*

**Leukemia**

Male	0.52	0	NC*
Female	0.37	0	NC*
Total	0.88	0	NC*

**Liver and Intrahepatic Bile Ducts**

Male	0.25	0	NC*
Female	0.09	0	NC*
Total	0.34	0	NC*

**Lung and Bronchus**

Male	3.41	4	NC*
Female	2.39	5	210
Total	5.80	9	155

**Testis**

Male	0.25	0	NC*
------	------	---	-----

**Thyroid**

Male	0.15	0	NC*
Female	0.39	0	NC*
Total	0.54	0	NC*

**Uteri, Corpus and Uterus, NOS**

Female	1.19	2	NC*
--------	------	---	-----

**All Sites / Types**

Male	22.00	20	91
Female	18.71	18	96
Total	40.71	38	93

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Rutland****Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	2.90	3	NC*	Male	2.20	6	273
Female	1.09	3	NC*	Female	1.67	1	NC*
Total	3.99	6	150	Total	3.87	7	181
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.04	1	NC*	Male	0.60	0	NC*
Female	0.78	1	NC*	Female	0.50	0	NC*
Total	1.82	2	NC*	Total	1.10	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.14	0	NC*	Male	2.62	3	NC*
Female	19.35	24	124	Female	2.16	5	231
Total	19.49	24	123	Total	4.78	8	167
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.18	1	NC*	Male	2.11	0	NC*
				Female	0.93	1	NC*
				Total	3.04	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	7.27	5	69	Female	2.27	4	NC*
Female	6.84	8	117				
Total	14.11	13	92				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			

Male	1.14	2	NC*	Male	1.27	1	NC*
Female	0.33	0	NC*	Female	1.24	1	NC*
Total	1.47	2	NC*	Total	2.51	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.55	0	NC*	Male	18.64	11	59
Female	0.40	0	NC*				
Total	0.95	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.92	3	NC*	Male	1.27	1	NC*
Female	1.10	3	NC*	Female	0.76	1	NC*
Total	3.02	6	199	Total	2.02	2	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.09	0	NC*	Male	0.85	1	NC*
Female	0.25	0	NC*				
Total	1.34	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.53	3	NC*	Male	0.48	0	NC*
Female	1.17	1	NC*	Female	1.23	1	NC*
Total	2.70	4	NC*	Total	1.71	1	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.74	0	NC*	Female	3.67	3	NC*
Female	0.28	0	NC*				
Total	1.01	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	9.45	4	NC*	Male	62.01	46	74 #-
Female	7.25	2	NC*	Female	58.65	61	104
Total	16.70	6	36 ~-	Total	120.65	107	89

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels